Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study

被引：1

作者：

Wang, Michael ^{[1
]}

Jurczak, Wojciech ^{[2
]}

Trneny, Marek ^{[3
]}

Belada, David ^{[4
]}

Wrobel, Tomasz ^{[5
]}

Ghosh, Nilanjan ^{[6
]}

Keating, Mary-Margaret ^{[7
]}

van Meerten, Tom ^{[8
]}

Fernandez Alvarez, Ruben ^{[9
]}

von Keudell, Gottfried ^{[10
]}

Thieblemont, Catherine ^{[11
]}

Peyrade, Frederic ^{[12
]}

Andre, Marc ^{[13
]}

Hoffmann, Marc ^{[14
]}

Glusman, Edith Szafer ^{[15
]}

Lin, Jennifer ^{[15
]}

Dean, James P. ^{[15
]}

Neuenburg, Jutta K. ^{[15
]}

Tam, Constantine S. ^{[16
,17
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA

[2] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland

[3] Gen Univ Hosp Prague, Prague, Czech Republic

[4] Charles Univ Prague, Dept Internal Med Haematol 4, Hosp & Fac Med, Hradec Kralove, Czech Republic

[5] Wroclaw Med Univ, Wroclaw, Poland

[6] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[7] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada

[8] Univ Med Ctr Groningen, Groningen, Netherlands

[9] Hosp Univ Cabuenes, Asturias, Spain

[10] Beth Israel Deaconess Med Ctr, Boston, MA USA

[11] Univ Paris, Hop St Louis, Assistance Publ Hop Paris, Serv Hematooncol, Paris, France

[12] Ctr Antoine Lacassagne, Nice, France

[13] CHU UCL Namur Mt Godinne, Yvoir, Belgium

[14] Univ Kansas, Ctr Canc, Kansas City, KS USA

[15] AbbVie, N Chicago, IL USA

[16] Alfred Hlth, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[17] Monash Univ, Melbourne, Vic, Australia

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2023-191921

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：LBA5 / LBA5

页数：1

共 50 条

[31] Clinical outcomes of ibrutinib in patients with relapsed or refractory mantle cell lymphoma: Korean multicenter, retrospective analysis
Yi, J. H.
Kim, W. S.
Kim, S. J.
Yoon, D. H.
Suh, C.
Chang, M. H.
Yang, D. H.
Jo, J-C.
Hyun, S. Y.
Eom, H-S.
Lee, J-O.
Kwon, J. H.
Han, S. H.
Lee, S-S.
Kwak, J-Y.
Kim, S. H.
ANNALS OF ONCOLOGY, 2019, 30
[32] IBRUTINIB PLUS WITH VENETOCLAX FOR THE TREATMENT OF PRIMARY REFRACTORY MANTLE-CELL LYMPHOMA: A REAL LIFE EXPERIENCE
Fabbri, A.
Cencini, E.
Congiu, A. G.
Miglino, M.
Rigacci, L.
Bocchia, M.
HAEMATOLOGICA, 2019, 104 : 161 - 161
[33] UPDATED INTERIM RESULTS OF AN INTERNATIONAL, MULTICENTER, PHASE 2 STUDY OF IBRUTINIB (PCI-32765) IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA
Rule, S.
Wang, M.
Martin, P.
Auer, R.
Kahl, B.
Jurczak, W.
Advani, R.
Romaguera, J.
Williams, M.
Barrientos, J.
Chmielowska, E.
Radford, J.
Stilgenbauer, S.
Troung, V.
McGreivy, J.
Clow, F.
Beaupre, D.
Kunkel, L.
Goy, A.
Blum, K.
HAEMATOLOGICA, 2013, 98 : 489 - 489
[34] A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404
Cohen, Jonathon B.
Portell, Craig A.
Hamadani, Mehdi
Jegede, Opeyemi
Diefenbach, Catherine
David, Kevin A.
Fletcher, Christopher D.
Landsburg, Daniel J.
Kahl, Brad S.
BLOOD, 2019, 134
[35] Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory and Untreated Mantle Cell Lymphoma: Safety, Efficacy, and Molecular Analysis
Melani, Christopher
Lakhotia, Rahul
Pittaluga, Stefania
Miljkovic, Milos D.
Phelan, James D.
Muppidi, Jagan R.
Thomas, Craig J.
Ceribelli, Michele
Juanitez, Anna Marie
Pradhan, Amynah
Hillsman, Amy
Steinberg, Seth M.
Jaffe, Elaine S.
Roschewski, Mark
Staudt, Louis M.
Wilson, Wyndham H.
BLOOD, 2021, 138
[36] Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study
Ansell, Stephen M.
Tang, Hui
Kurtin, Paul J.
Koenig, Patricia A.
Inwards, David J.
Shah, Keith
Ziesmer, Steven C.
Feldman, Andrew L.
Rao, Radha
Gupta, Mamta
Erlichman, Charles
Witzig, Thomas E.
LANCET ONCOLOGY, 2011, 12 (04): : 361 - 368
[37] TEMSIROLIMUS FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: SUPPORTIVE EFFICACY ANALYSES FROM THE PHASE 3 STUDY
Hess, G.
Romaguera, J.
Herbrecht, R.
Verhoef, G.
Crump, M.
Hanushevsky, O.
Strahs, A.
Hewes, B.
Berkenblit, A.
Coiffier, B.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 391 - 392
[38] Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
Fisher, Richard I.
Bernstein, Steven H.
Kahl, Brad S.
Djulbegovic, Benjamin
Robertson, Michael J.
de Vos, Sven
Epner, Elliot
Krishnan, Amrita
Leonard, John P.
Lonial, Sagar
Stadtmauer, Edward A.
O'Connor, Owen A.
Shi, Hongliang
Boral, Anthony L.
Goy, Andre
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) : 4867 - 4874
[39] Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study
Zhang, Yuchen
Liu, Panpan
Cai, Jun
Jing, Hongmei
Zou, Liqun
Huang, Huiqiang
Wu, Yuanbin
Li, Wenyu
Zhong, Liye
Jin, Xueli
Ye, Xu
Feng, Ru
Zhang, Huilai
Zhang, Liling
Lin, Lie
Sun, Xiuhua
Tian, Yuyang
Xia, Zhongjun
Li, Zhiming
Huang, He
Xia, Yi
Cai, Qingqing
CANCER MEDICINE, 2022, 11 (22): : 4134 - 4145
[40] Economic Evaluation for the US of Ibrutinib Versus Acalabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma
Alrawashdh, Neda
Alkhatib, Nimer
McBride, Ali
Persky, Daniel
Abraham, Ivo
BLOOD, 2018, 132

← 1 2 3 4 5 →